NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC.
NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC.
NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC.
30 Jul 2025 (48 Days) Date | | - Cons. EPS | - EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
20 Feb 2025 Date | | - Cons. EPS | - EPS |
31 Oct 2024 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | - EPS |
30 Jul 2025 (48 Days) Date | | - Cons. EPS | - EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
20 Feb 2025 Date | | - Cons. EPS | - EPS |
31 Oct 2024 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | - EPS |
Medical - Devices Industry | Healthcare Sector | Mr. Quentin S. Blackford CEO | XSTU Exchange | US4500561067 ISIN |
US Country | 2,000 Employees | - Last Dividend | - Last Split | 20 Oct 2016 IPO Date |
iRhythm Technologies, Inc. is a pioneering digital healthcare organization primarily focused on the design, development, and deployment of innovative device-based solutions aimed at the ambulatory cardiac monitoring sector within the United States. Leveraging advanced technology, the company's mission revolves around facilitating the diagnosis of arrhythmias—irregular heartbeats that can lead to serious health issues. The essence of iRhythm's offering is encapsulated in its commitment to enhancing cardiac care through digital innovation, where it brings a unique blend of clinical expertise and technological prowess. Established in 2006 and based in San Francisco, California, the company has established itself as a key player in the realm of cardiac healthcare by offering groundbreaking services that significantly improve patient outcomes. Additionally, iRhythm Technologies maintains a collaborative development agreement with Verily Life Sciences LLC and Verity Ireland Limited, focusing on the creation of cutting-edge atrial fibrillation screening, detection, and monitoring products, thereby broadening its impact on patients' lives.
iRhythm provides the Zio services as an innovative ambulatory monitoring solution that caters to the needs of patients requiring long-term, short-term continuous monitoring, and mobile cardiac telemetry monitoring services. The essence of Zio services lies in their ability to offer comprehensive cardiac monitoring, thereby facilitating timely and accurate diagnosis of arrhythmias. Through Zio services, patients benefit from a sophisticated monitoring approach that combines convenience with clinical efficacy.
At the heart of iRhythm's product lineup is the Zio Monitor System, a state-of-the-art remote electrocardiogram (ECG) monitoring system that includes a wearable patch ECG monitor. Capable of recording the electrical signals from the heart continuously for up to 14 days, this system exemplifies the seamless integration of technology and healthcare. In conjunction with the Zio ECG Utilization Software System, it supports the comprehensive capture and analysis of ECG data, including the identification of specific arrhythmia events. The system is prescription-only, emphasizing its role as a sophisticated diagnostic tool in the hands of healthcare professionals.
The Zio XT System represents the previous generation of the Zio Monitor System, maintaining its role as a vital tool for remote ECG monitoring. Also designed to be worn for up to 14 days, the Zio XT patch continuously records the heart's electrical activity, offering a blend of reliability and convenience for patients. As a prescription-only system, it underscores iRhythm's commitment to delivering professional-grade cardiac monitoring solutions.
Last but not least, the Zio AT System extends the capabilities of remote ECG monitoring with its innovative design. Similar to its predecessors, it features a patch that records the heart's electrical signals continuously for up to 14 days. Unique to the Zio AT system, however, is the inclusion of the Zio AT wireless gateway. This addition enhances connectivity between the Zio AT patch and the ZEUS System during the patient wear period, ensuring real-time data transmission and analysis. This system is also prescription-only, providing an advanced tool for healthcare providers in the management and diagnosis of cardiac conditions.